The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Changing perceptions of MGUS progression: explaining the data
Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses his research into the progression of monoclonal gammopathy (MGUS) into multiple myeloma (MM), and the findings which indicate that risk assessment needs to be carried out more frequently. He also highlights how not all MGUS goes through a smoldering myeloma phase. This interview took place at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
